Status:
RECRUITING
Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis
Lead Sponsor:
Bone Biologics Corp
Conditions:
Degenerative Disc Disease
Spondylolisthesis
Eligibility:
All Genders
17-70 years
Phase:
NA
Brief Summary
The objective of this clinical study is to evaluate the safety and effectiveness of NB1 Bone Graft in subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion. It is ...
Eligibility Criteria
Inclusion
- Documented diagnosis of degenerative disc disease
- Up to Grade I spondylolisthesis
- Eligible to undergo a single vertebral level spine fusion (L2 to S1)
Exclusion
- Previous spinal instrumentation or previous interbody fusion procedure at the involved level
- Grade II or greater spondylolisthesis
- Systemic or local infection at the site of surgery
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03810573
Start Date
March 1 2024
End Date
June 1 2026
Last Update
March 12 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Monash Medical Center
Clayton, Victoria, Australia, 3168
2
St Vincent Melbourne
Fitzroy, Australia
3
St George Hospital
Kogarah, Australia